The primary objective of the dose-escalation study is to assess the safety and tolerability of intravenous PRTX-100 administered weekly in patients with active RA on methotrexate therapy...The first sequential dose escalation part of this Phase 1b study will enroll up to 40 patients and is expected to be completed in the second quarter of 2011

The company also said it is rapidly advancing toward the initiation of its Phase II PROACT proof-of-concept trial of the drug in advanced prostate cancer and is on track to begin clinical evaluation later this year in glioblastoma multiforme...The company said it plans to soon start its first-in-man Phase I dose-escalation trial of LOR-253 in advanced or metastatic solid tumors to assess the safety profile, tolerability and antitumor activity of the drug candidate and its pharmacokinetic and

Bionovo plans to study Bezielle in patients with pancreatic cancer to initiate a Phase I/II dose escalation trial, but the company has not yet submitted an investigational new drug application...Excelimmune, of Woburn, Mass., has raised $4.5 million in new financing for its planned clinical development work on polyclonal antibodies

The dose-escalation study will enroll about 30 healthy subjects, with safety and tolerability the primary objectives...Data were presented at the European Academy of Allergy and Clinical Immunology in London

The following data were revealed at the American Society of Clinical Oncology meeting in Chicago...Ariad Pharmaceuticals Inc., of Cambridge, Mass., said updated data from an ongoing Phase I study confirmed strong clinical evidence of hematologic, cytogenetic and molecular anti-leukemia activity of AP24534, a multitargeted kinase inhibitor, in heavily pretreated patients with chronic myeloid leukemia, including those with the T315I mutation of the target protein Bcr-Abl...BioTheranostics, of San Diego

In the study, 18 patients who previously failed treatment with Bacillus Calmette-Guerin were randomized to receive six weekly intravesicular-instillations of nab-paclitaxel beginning at a dose of 150 mg, with a dose-escalation model used until a maximal deliverable dose was identified...Astex Therapeutics, of Cambridge, UK, said interim data from an ongoing Phase I study of HSP90 inhibitor AT13387, which is to be presented at the American Society of Clinical Oncology Annual Meeting, indicated that

More detailed results will be presented at the American Society of Clinical Oncology annual meeting in June...Genetix plans to initiate larger clinical studies in ALD in both the U.S...Jennerex Inc., of San Francisco, reported positive results from its Phase I dose-escalation study evaluating the intravenous administration of JX-594 to patients with metastatic cancer

The first clinical study, to be funded by the National Institute of Allergy and Infectious Disease, will enroll 72 healthy adult volunteers to receive injections of placebo, a lower dose or a higher dose of the investigational vaccine...The dose-escalation study will test three dose levels and cohorts of three to six patients to determine a maximum-tolerated dose

The randomized, controlled, double-blinded, dose-escalation study is being conducted in Burkina Faso and is funded by the NIH's National Institute of Allergy and Infectious Diseases...The Alzheimer's trial is a placebo-controlled, dose-ranging safety and efficacy study that will measure improvement in procognitive effects and clinical condition

Cytori Therapeutics Inc., of San Diego, said the first clinical trial of adipose (fat) tissue-derived stem and regenerative cells (ADRCs) for the treatment of no-option chronic heart disease patients showed the procedure was safe and feasible...Nile Therapeutics Inc., of San Francisco, completed the dose escalation stage of an ongoing Phase II study of CD-NP in patients with acute decompensated heart failure

The first part of the trial is an open-label, dose-escalation trial that will enroll up to 80 patients and test Debio 0932 as a single agent to find the recommended dose for the second part of the trial...Icagen said it currently expects that the clinical studies at higher doses may be completed during the second half of this year, subject to available funding

Stemedica Cell Technologies Inc., of San Diego, said the FDA approved an investigational new drug application for clinical testing of its allogeneic mesenchymal bone marrow-derived stem cells in ischemic stroke patients...The planned Phase I/II dose-escalation study will involve patients with significant functional or neurologic impairment related to ischemic stroke

Stemedica Cell Technologies Inc., of San Diego, filed an investigational new drug application with the FDA for a Phase I/II dose-escalation trial of allogeneic mesenchymal bone marrow cells in patients who are functionally or neurologically impaired following a stroke...The primary objective in the Phase I portion is to determine the recommended dose for Phase II, which is designed to measure clinical response rate

Amsterdam Molecular Therapeutics, of Amsterdam, the Netherlands, dosed the first patient in the Phase I/II exploratory trial with a gene therapy product for hemophilia B. The trial is an open-label, dose-escalation study using a vector-gene combination developed at St. Jude Children's Research Hospital...Evotec AG, of Hamburg, Germany, completed the clinical part of the first Phase I trial of its NR2B-selective NMDA receptor antagonist EVT 103, showing that the compound was safe and well tolerated

The placebo-controlled, dose-escalation study will involve four cohorts of eight patients each...Those data were presented at the American Society of Clinical Oncology's Genitourinary Cancers Symposium in San Francisco

The study is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug will be given to all patients who participate...Vertex expects to obtain interim clinical data, including safety and viral kinetic data, from the trial in the second half of the year

The open-label, dose-escalation study plans to enroll approximately 24 patients to determine the maximum-tolerated dosage in addition to determining the safety and pharmacokinetics of the drug...clinical sites into two ongoing randomized, double-blind Phase II trials of its lead product, nimotuzumab, a humanized monoclonal antibody

Biotie Therapies Corp., of Turku, Finland, reported positive top-line data from a clinical study with the VAP-1 antibody in rheumatoid arthritis, with BTT-1023 showing itself to be well tolerated and with signals of therapeutic activity...Data from the randomized, double-blind, placebo-controlled, 135-patient, European, dose-escalation trial are expected in the first half of 2012

The double-blind, placebo-controlled, dose escalation safety study in healthy subjects is being conducted at the St. Louis University Center for Vaccine Development...In addition, the trial will assess the drug's safety and tolerability and will follow duration of clinical symptoms and global functionality